Mayo Clinic questions FDA drug warning

Oct 01, 2007

A Mayo Clinic study has brought into question a U.S. Food and Drug Administration warning about the use of a medication to control nausea during surgery.

The 2001 FDA warning against using droperidol was based on concerns the drug contributed to potentially fatal heart arrhythmias.

The Mayo Clinic compared 139,932 patients' responses before the warning was issued and found no proven cases of complications directly attributable to droperidol. In comparison, after the FDA warning, two of 151,256 patients suffered poor heart rhythm while receiving alternative medications. The percentage of patients who received droperidol was 12 percent prior to the warning and 0 percent after the FDA warning was issued.

Based on their findings, Mayo Clinic anesthesiologists said they believe the FDA warning was unnecessary.

"In our study, we obtained results that were just the opposite of what the FDA action would predict," said Dr. Gregory Nuttal, the study's lead investigator. "We actually had fewer complications with droperidol."

The study is believed the first large, statistically well-controlled investigation of patient responses to droperidol at a single medical center over a long period of time and which included treatment before and after the FDA warning.

Copyright 2007 by United Press International

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

Pfizer anti-smoking drug has heart risks: US

Jun 16, 2011

US regulators said Thursday that the label on Pfizer's anti-smoking drug Chantix must be changed to warn of a slightly higher risk of heart problems in patients who already have cardiovascular disease.

US takes aim at purported sex disease 'cures'

May 03, 2011

The US government said Tuesday it is taking steps to remove from the market a host of online products that promise to cure HIV, herpes, chlamydia and other sexually transmitted diseases.

Watchdog group makes 2nd push to ban diet pill

Apr 18, 2011

(AP) -- For the second time in five years, public health advocates are calling on the Food and Drug Administration to ban a fat-blocking drug sold over-the counter and via prescription, pointing to new reports of kidney ...

Researchers discuss sugar's highs, lows

Mar 24, 2011

America's growing sweet tooth is super-sizing waistlines and the nation's health care price tag, warn University of California researchers. People in the U.S. are eating 21 times more sweet stuff today than the pilgrims and ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0